Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Title:	A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)
Authors:	Leng, Xiaomei^Aff1; Leszczyński, Piotr^Aff2; Jeka, Slawomir^Aff3; Liu, Shengyun^Aff4; Liu, Huaxiang^Aff5; Miakisz, Malgorzata^Aff6; Gu, Jieruo^Aff7; Kilasonia, Lali^Aff8; Stanislavchuk, Mykola^Aff9; Yang, Xiaolei^Aff10; Zhou, Yinbo^Aff10; Dong, Qingfeng^Aff10; Mitroiu, Marian^Aff11; Addison, Janet^Aff12; Rezk, Mourad F.^Aff11; Zeng, Xiaofeng^{Aff1, IDs1307502403375w_cor16}
Source:	Arthritis Research & Therapy. 26(1)
Database:	Springer Nature Journals